

# Emidio Scarpellini

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3401569/emidio-scarpellini-publications-by-year.pdf>

**Version:** 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

52  
papers

1,506  
citations

20  
h-index

38  
g-index

56  
ext. papers

1,886  
ext. citations

4.3  
avg, IF

4.39  
L-index

#	Paper	IF	Citations
52	Postinfectious onset in functional dyspepsia is a risk factor for weight loss.. <i>Journal of Gastroenterology</i> , <b>2022</b> , 57, 156	6.9	
51	Zinc and gut microbiota in health and gastrointestinal disease under the COVID-19 suggestion.. <i>BioFactors</i> , <b>2022</b> ,	6.1	2
50	The role of gut microbiota in gastrointestinal diseases: the heart of the matter.. <i>Minerva Gastroenterology</i> , <b>2021</b> , 67, 312-313	3	0
49	Probiotics and obesity associated disease: an extended view beyond traditional strains.. <i>Minerva Gastroenterology</i> , <b>2021</b> , 67, 348-356	3	1
48	Gut microbiota and non-alcoholic fatty liver disease: a narrative review. <i>Minerva Gastroenterology</i> , <b>2021</b> ,	3	2
47	Nutritional Status and the Critically Ill Patient: Gut Microbiota and Immuno-Nutrition in I.C.U. at the Time of SARS-COV 2 Pandemic. <i>Gastroenterology Insights</i> , <b>2021</b> , 12, 259-269	2.1	0
46	Probiotics and gut health. <i>Minerva Gastroenterology</i> , <b>2021</b> ,	3	1
45	Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review. <i>Reviews on Recent Clinical Trials</i> , <b>2021</b> , 16, 138-145	1.2	10
44	Hepatocellular carcinoma in patients with chronic renal disease: Challenges of interventional treatment. <i>Surgical Oncology</i> , <b>2021</b> , 36, 42-50	2.5	4
43	Reply to: Late dumping syndrome or postprandial reactive hypoglycaemic syndrome after bariatric surgery. <i>Nature Reviews Endocrinology</i> , <b>2021</b> , 17, 317-318	15.2	
42	From Pre- and Probiotics to Post-Biotics: A Narrative Review.. <i>International Journal of Environmental Research and Public Health</i> , <b>2021</b> , 19,	4.6	7
41	International consensus on the diagnosis and management of dumping syndrome. <i>Nature Reviews Endocrinology</i> , <b>2020</b> , 16, 448-466	15.2	50
40	A survey on the impact of the COVID-19 pandemic on motility and functional investigations in Europe and considerations for recommencing activities in the early recovery phase. <i>Neurogastroenterology and Motility</i> , <b>2020</b> , 32, e13926	4	7
39	The mechanism of dysbiosis in alcoholic liver disease leading to liver cancer. <i>Hepatoma Research</i> , <b>2020</b> , 6,	4.3	10
38	Gut Microbiota and Liver Interaction through Immune System Cross-Talk: A Comprehensive Review at the Time of the SARS-CoV-2 Pandemic. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	15
37	The Role of GI Peptides in Functional Dyspepsia and Gastroparesis: A Systematic Review. <i>Frontiers in Psychiatry</i> , <b>2020</b> , 11, 172	5	14
36	Liver Cirrhosis Complications Management at the Emergency Department. <i>Reviews on Recent Clinical Trials</i> , <b>2020</b> , 15, 331-338	1.2	1

35	Effects of enteral nutrition on patients with pressure lesions: a single center, pilot study. <i>European Review for Medical and Pharmacological Sciences</i> , <b>2020</b> , 24, 1563-1570	2.9	0
34	Gut Microbiota and Obesity: A Role for Probiotics. <i>Nutrients</i> , <b>2019</b> , 11,	6.7	144
33	The effect of arabinosylooligosaccharides on upper gastroduodenal motility and hunger ratings in humans. <i>Neurogastroenterology and Motility</i> , <b>2018</b> , 30, e13306	4	1
32	Impact of patients nutritional status on major surgery outcome. <i>European Review for Medical and Pharmacological Sciences</i> , <b>2018</b> , 22, 3524-3533	2.9	10
31	Effect of methylnaltrexone and naloxone on esophageal motor function in man. <i>Neurogastroenterology and Motility</i> , <b>2017</b> , 29, e12938	4	9
30	Gut microbiota changes and chronic hepatitis C virus infection. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2017</b> , 11, 813-819	4.2	48
29	Eluxadolone for the treatment of diarrhoea-predominant irritable bowel syndrome. <i>Expert Opinion on Pharmacotherapy</i> , <b>2016</b> , 17, 1395-402	4	9
28	Motilin-induced gastric contractions signal hunger in man. <i>Gut</i> , <b>2016</b> , 65, 214-24	19.2	56
27	Gut Microbiota and Alcoholic Liver Disease. <i>Reviews on Recent Clinical Trials</i> , <b>2016</b> , 11, 213-9	1.2	17
26	Effect of baclofen on gastric acid pocket in subjects with gastroesophageal reflux disease symptoms. <i>Ecological Management and Restoration</i> , <b>2016</b> , 29, 1054-1063	3	9
25	The effect of arabinosylooligosaccharides on gastric sensory-motor function and nutrient tolerance in man. <i>Neurogastroenterology and Motility</i> , <b>2016</b> , 28, 1194-203	4	5
24	The human gut microbiota and virome: Potential therapeutic implications. <i>Digestive and Liver Disease</i> , <b>2015</b> , 47, 1007-12	3.3	162
23	Effect of baclofen on the acid pocket at the gastroesophageal junction. <i>Ecological Management and Restoration</i> , <b>2015</b> , 28, 488-95	3	7
22	Probiotics in non-alcoholic fatty liver disease: which and when. <i>Annals of Hepatology</i> , <b>2013</b> , 12, 357-63	3.1	12
21	Obesity and metabolic syndrome: an inflammatory condition. <i>Digestive Diseases</i> , <b>2012</b> , 30, 148-53	3.2	74
20	Food allergy: from diagnosis to treatment. <i>Digestive Diseases</i> , <b>2012</b> , 30, 224-31	3.2	2
19	Role of gut microbiota in food tolerance and allergies. <i>Digestive Diseases</i> , <b>2011</b> , 29, 540-9	3.2	22
18	The effects of itopride on oesophageal motility and lower oesophageal sphincter function in man. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 33, 99-105	6.1	26

17	Effect of rimonabant on oesophageal motor function in man. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 33, 730-7	6.1	20
16	Modulation of the postprandial acid and bile pockets at the gastro-oesophageal junction by drugs that affect gastric motility. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 33, 1370-7	6.1	20
15	Prevalence of small intestinal bacterial overgrowth in Parkinson's disease. <i>Movement Disorders</i> , <b>2011</b> , 26, 889-92	7	115
14	Reproducibility and agreement of pharyngeal automated impedance manometry with videofluoroscopy. <i>Clinical Gastroenterology and Hepatology</i> , <b>2011</b> , 9, 862-7	6.9	60
13	Endocannabinoid control of gastric sensorimotor function in man. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2010</b> , 31, 1123-31	6.1	24
12	Small intestinal bacterial overgrowth and intestinal permeability. <i>Scandinavian Journal of Gastroenterology</i> , <b>2010</b> , 45, 1131-2	2.4	23
11	The interaction between small intestinal bacterial overgrowth and warfarin treatment. <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104, 2364-5	0.7	4
10	Prevalence of small intestinal bacterial overgrowth in children with irritable bowel syndrome: a case-control study. <i>Journal of Pediatrics</i> , <b>2009</b> , 155, 416-20	3.6	60
9	Probiotics: which and when?. <i>Digestive Diseases</i> , <b>2008</b> , 26, 175-82	3.2	21
8	Regression of lactose malabsorption in coeliac patients after receiving a gluten-free diet. <i>Scandinavian Journal of Gastroenterology</i> , <b>2008</b> , 43, 174-7	2.4	12
7	Renzapride: a new drug for the treatment of constipation in the irritable bowel syndrome. <i>Expert Opinion on Investigational Drugs</i> , <b>2008</b> , 17, 1663-70	5.9	13
6	Fecal calprotectin concentrations in patients with small intestinal bacterial overgrowth. <i>Digestive Diseases</i> , <b>2008</b> , 26, 183-6	3.2	23
5	High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2007</b> , 25, 781-6	6.1	80
4	Association between hypothyroidism and small intestinal bacterial overgrowth. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2007</b> , 92, 4180-4	5.6	79
3	Small intestinal bacterial overgrowth: diagnosis and treatment. <i>Digestive Diseases</i> , <b>2007</b> , 25, 237-40	3.2	113
2	Efficacy of butyrate in the treatment of diarrhoea-predominant irritable bowel syndrome. <i>Digestive and Liver Disease Supplements</i> , <b>2007</b> , 1, 19-22		0
1	Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2005</b> , 22, 31-5	6.1	95